Welcome to our Investor Center. Our center is designed to provide you with convenient access to company information. For additional information on our portfolio of product candidates, please visit Pipeline.
SAN DIEGO--(BUSINESS WIRE)--Mar. 5, 2014--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today announced that it will present at the
following investor conferences:
The Cowen and Company 34th Annual Health Care Conference on
SAN DIEGO--(BUSINESS WIRE)--Mar. 4, 2014--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the pricing
of an underwritten public offering of 6,400,000 shares of its common
stock, offered at a price to the public of $28.50 per share. The gross
proceeds from this offering to ACADIA are expected to be $182.4 million,
before deducting underwriting discounts and commissions and other
estimated offering expenses payable by ACADIA. ACADIA has granted...
SAN DIEGO--(BUSINESS WIRE)--Mar. 3, 2014--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it
intends to offer and sell, subject to market and other conditions,
$150,000,000 of shares of its common stock in an underwritten public
offering. There can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the offering.
Jefferies LLC and J.P. Morgan Securities LLC are acting as the j...
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.